Tests vagus nerve stimulation for treatment-resistant depression
Tests a implanted nerve device against usual care in adults with depression that resists treatment.
Plain-language title generated from the registry record
Registry title: Treatment Resistant Depression and Vagus Nerve Stimulation
Key facts
- Where
- Angers, Bordeaux, Brest, Caen, Clermont-Ferrand, Colombes, Créteil, Dijon, Grenoble, Issy-les-Moulineaux, Le Kremlin-Bicêtre, Lille, Lyon, Marseille, Nantes, Nice, Paris, Poitiers, Rennes, Rouen, Saint-Etienne, Toulouse, and Tours, FranceSee the 24 sites
Where in France
- CHU AngersAngers, FranceNo longer taking part
- Centre Hospitalier Charles PerrensBordeaux, FranceTaking people
- Chu BrestBrest, FranceNot yet recruiting
- CHU CaenCaen, FranceNot yet recruiting
- CHU Clermont Ferrand - Hôpital Gabriel MontpiedClermont-Ferrand, FranceTaking people
- AP-HP. Nord - Université de Paris, Hôpital Louis MourierColombes, FranceNo longer taking part
- APHP. Hôpitaux Universitaires Henri Mondor, Hôpital Henri MondorCréteil, FranceTaking people
- CHU Dijon, Hôpital Le BocageDijon, FranceTaking people
- CHU Grenoble AlpesGrenoble, FranceTaking people
- AP-HP. Centre - Université de Paris, Hôpital Corentin-CeltonIssy-les-Moulineaux, FranceNo longer taking part
- AP-HP. Université Paris Saclay, Hôpital BicêtreLe Kremlin-Bicêtre, FranceNo longer taking part
- CHU LilleLille, FranceTaking people
- Hospices Civils de Lyon, Hôpital Pierre WertheimerLyon, FranceNot yet recruiting
- Assistance Publique Hôpitaux de Marseille, Hôpital de la ConceptionMarseille, FranceNot yet recruiting
- CHU de Nantes - Hôtel DieuNantes, FranceTaking people
- CHU Nice, Hôpital Pasteur 1Nice, FranceTaking people
- GHU Paris Psychiatrie & Neuroscience, site Saint AnneParis, FranceTaking people
- AP-HP. Sorbonne Université, Hôpital La Pitié SalpetrièreParis, FranceNo longer taking part
- Centre Hospitalier Henri LaboritPoitiers, FranceNot yet recruiting
- Centre hospitalier Guillaume RégnierRennes, FranceTaking people
- CHU Rouen, Centre Hospitalier du RouvrayRouen, FranceTaking people
- CHU Saint-EtienneSaint-Etienne, FranceTaking people
- CHU Toulouse, Hôpital de PsychiatrieToulouse, FranceTaking people
- CHRU Tours, Clinique Psychiatrique UniversitaireTours, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT05952674
- Record updated
- 23 June 2026
- Original description
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide.Read full original descriptionShow less
Resistant Depression and Vagus Nerve Stimulation : a Medico-economic, Multicenter, Randomized and Open Trial
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide.
Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption.
Sometimes, TRD is part of a bipolar illness. In this case, the challenge is even bigger because antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients.
The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response.
The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing long-term recurrences, and therefore responding to the lack of effective maintenance treatment in TRD. In fact, the benefits of VNS gradually accumulate over 12-24 months, which makes it complementary to more incisive treatments like ECT. Finally, its efficacy-tolerance profile appears to be similar in uni and bipolar TRD, giving VNS a potentially unique place in the therapeutic arsenal in psychiatry.
The DepVNS hypothesis is that VNS is a medico-economically efficient therapeutic option to overcome the therapeutic impasse in which patients suffering from uni and bipolar DR currently find themselves due to the frequency of relapses under treatment.
The primary objective is to estimate, from a collective point of view, the incremental cost-utility ratio of VNS to treat patients suffering from RD.
Inclusion: Patients aged 18 years and older ; Childbearing women must have an efficient contraception for the whole study period; Diagnosis of recurrent depressive trouble or persistent depressive disorder or bipolar disorder (according to DSM-5); Start of disorder (defined by the occurrence of the first thymus episode: characterized depressive disorder or maniac episode with or without mixed characteristics) for 5 years or more; At least one of the following criteria:; Criterion A: current characterized depressive disorder and characterized depressive disorder for at least 12 months during the last 24 months despite at least four treatments lines at appropriate dosage and duration; Criterion B: current treatment by ECT/(Es)Ketamine/TMS and criteria A before the start treatment or ECT/(Es)Ketamine/TMS dependency; Patients who, after the nature of the study has been explained to them, have given written consent.
Exclusion: Characterized depressive disorder with psychotic characteristics within 3 months before the inclusion (DSM-5); Concomitant participation to another interventional research not authorized by the coordinating investigator or the scientific lead. Participation to non-interventional researches is allowed; Patients receiving enforced cares (ASPDT, ASPPI, ASPDRE, etc.); Surgical contraindication to the VNS; Schizophrenia, schizoaffective disorder or persistent delusional disorder (DSM-5); Disability, according to the investigator, to understand the study or refusal to sign the study consent form (non-francophone patient, cognitive disorders); Anticipated disability to attend all the visits, treatments and measures planned by the protocol: severe personality disorder, severe substance addiction, severe intellectual development disorder. In any of those cases, the notion of severity is at the indiscretion of the investigator; Secondary Exclusion Criteria:; Know pregnancy or breastfeeding; Non-affiliation to a social security regimen or any other social protection regimen; Positive β-HCG (results obtained after the informed consent is signed but before the randomization).